Identificador persistente para citar o vincular este elemento: https://accedacris.ulpgc.es/jspui/handle/10553/149414
Título: Extra-virgin olive oil and additional cardiovascular outcomes in the PREDIMED Trial: An outcome-wide perspective
Autores/as: de Rojas, Javier Pérez
Toledo, Estefania
Estruch, Ramón
Guasch-Ferré, Marta
Salas-Salvadó, Jordi
Gómez-Gracia, Enrique
Ros, Emilio
Fitó, Montse
Arós, Fernando
Fiol, Miquel
Lapetra, José
Serra Majem, Luis 
Pintó, Xavier
Sorlí, José V.
Babio, Nancy
Castañer, Olga
Alonso-Gómez, Ángel M.
Martínez-González, Miguel Ángel
Jiménez-Moleón, José Juan
Clasificación UNESCO: 32 Ciencias médicas
320501 Cardiología
3206 Ciencias de la nutrición
Palabras clave: Peripheral Artery-Disease
Mediterranean Diet
Heart-Failure
Risk
Consumption, et al.
Fecha de publicación: 2025
Publicación seriada: The American heart journal 
Resumen: Background: Olive oil, increasingly consumed in the U.S., has been inversely associated with cardiovascular disease (CVD) risk. However, previous studies did not assess a broad spectrum of CVD outcomes, incorporated repeated annual dietary assessments, or distinguished between polyphenol-rich EVOO and common olive oil (COO), which lacks these compounds. Methods: We assessed 7102 high-risk participants from the PREDIMED trial (57.5% women; aged 55-80 years), all free of CVD at baseline. Olive oil consumption was assessed annually, and cumulative average intakes of EVOO and COO were calculated. The primary outcome was a composite of myocardial infarction, stroke, peripheral arterial disease, heart failure, atrial fibrillation, or cardiovascular death, whichever occurred first. Individual outcomes were also evaluated. Time-dependent Cox models were adjusted for major confounders, including trial intervention arm. Results: Over a median follow-up of 4.7 years, 621 participants experienced at least one CVD event. Participants in the highest tertile of cumulative EVOO intake (mean: 49.2 g/d) had a 25% lower risk of the composite outcome (HR: 0.75; 95% CI: 0.60-0.94), with significant reductions in several individual CVD outcomes. In the decile analysis, the highest (mean: 60.9 g/d) versus lowest decile had a 48% lower risk (HR: 0.52; 95% CI: 0.35 to 0.79). COO consumption was not significantly associated with CVD risk when mutually adjusted for EVOO (HRper 10 g/d: 0.93; 95% CI: 0.87-1.00). Conclusions: High consumption of EVOO is associated with a substantial reduction in the risk of an outcome-wide composite of CVD events among high-risk individuals. In contrast, COO, which lacks polyphenols, showed weaker associations, highlighting the importance of differentiating olive oil types in CVD prevention strategies. Trial Registration: This trial was registered in the ISRCTN registry (ISRCTN 35739639): https://www.isrctn.com/ISRCTN35739639.
URI: https://accedacris.ulpgc.es/jspui/handle/10553/149414
ISSN: 0002-8703
DOI: 10.1016/j.ahj.2025.08.021
Fuente: American Heart Journal[ISSN 0002-8703],v. 291, p. 175-185, (Enero 2026)
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.